Skip to content
Screener

Vor Biopharma VOR Total Equity

Total Equity at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$84.97B+8.3%
Amgen logo
AmgenAMGN
$11.69B+57.4%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$20.25B+17.9%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$1.2B+266%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$408.73M-30.8%
Vera Therapeutics logo
Vera TherapeuticsVERA
$499.7M-6.6%

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation

See full
Market cap$1.28B+416%
Enterprise value$1.12B+902%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Reported directly by Vor Biopharma in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Vor Biopharma’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 8:31 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-220689
(in thousands, except share and per share amounts)March 31, 2026December 31, 2025
Stockholders’ deficit(1):
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 0 shares issued and outstanding as of March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value; 800,000,000 and 400,000,000 shares authorized as of March 31, 2026 and December 31, 2025, respectively; 54,185,582 and 38,720,196 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively1918
Additional paid-in capital1,222,823988,604
Accumulated other comprehensive (loss) income(706)41
Accumulated deficit(1,372,560)(1,152,975)
Total stockholders’ deficit(150,424)(164,312)
Total liabilities and stockholders’ deficit$506,746$464,126

Item 1. Financial Statements (Unaudited).

FAQ

What is Vor Biopharma's total equity?
Vor Biopharma (VOR) reported total equity of -$150.42M in Q1 2026.
How has Vor Biopharma's total equity changed year-over-year?
Vor Biopharma's total equity decreased by 327.7% year-over-year, from $66.07M to -$150.42M.
What is the long-term trend for Vor Biopharma's total equity?
Over 5 years (2020 to 2025), Vor Biopharma's total equity has grown at a 22.7% compound annual growth rate (CAGR), from -$59.07M to -$164.31M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Vor Biopharma's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude